BCL2 and gastric cancer: Relevant evidence in other types of cancer includes the ERK1-mediated phosphorylation of BCL2 and its subsequent removal by Beclin-1 leading to the promotion of autophagy in a human lung cancer cell line [49] and the enhancement in the activity of the MEK/ERK pathway after azacitidine treatment in gastric cancer [51].